Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov:46:102476.
doi: 10.1016/j.msard.2020.102476. Epub 2020 Aug 29.

Normal antibody response after COVID-19 during treatment with cladribine

Elisabeth G Celius  1
Affiliations

Normal antibody response after COVID-19 during treatment with cladribine

Elisabeth G Celius. Mult Scler Relat Disord. 2020 Nov.

Abstract

Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies three months later.

Keywords: COVID-19; Cladribine; Multiple sclerosis; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

Dr. Celius reports personal fees from Almirall, personal fees from Biogen, personal fees from Merck, personal fees from Roche, grants and personal fees from Novartis, grants and personal fees from Sanofi, personal fees from Teva, outside the submitted work.

References

    1. Brownlee W., Bourdette D., Broadley S., Killestein J., Ciccarelli O. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. 2020 - PubMed
    1. Baker D., Amor S., Kang A.S., Schmierer K., Giovannoni G. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. Mult. Scler. Relat. Disord. 2020;43 - PMC - PubMed
    1. Conte W.L. Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia. Mult. Scler. Relat. Disord. 2020;44 - PMC - PubMed
    1. Comi G., Cook S., Giovannoni G., Rieckmann P., Sørensen P.S., Vermersch P. Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult. Scler. Relat. Disord. 2019;29:168–174. - PubMed
    1. Cook S., Leist T., Comi G., Montalban X., Giovannoni G., Nolting A. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis. Mult. Scler. Relat. Disord. 2019;29:157–167. - PubMed

LinkOut - more resources